GoodRx Holdings, Inc. Class A Common Stock (GDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
Prescription fills for blockbuster weight loss medications in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments. That's according to new data from drug savings company GoodRx, which examined fill trends and spending patterns for weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
GoodRx initiated with a Neutral at Mizuho
Mizuho analyst Steven Valiquette initiated coverage of GoodRx with a Neutral rating and $5 price target. Following an "upbeat analyst meeting" in May that included 6%-12% revenue compound annual growth rate guidance for 2024-2026, store closures announced this year by several large retail drug chains now negatively impact GoodRx's second half of 2024 and 2025 outlook, says the analyst, who believes this has already put 2026 guidance "in jeopardy."
Why GoodRx Holdings Stock Was Sinking This Week
The company is growing key fundamentals. However, the improvements weren't enough to impress the market.
GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.
GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
GoodRx and CVS Sued for Suppressing Pharmacy Reimbursement
Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of pharmacy benefit managers (PBMs) — CVS's Caremark unit and Express Scripts — have all been named in at least three lawsuits by independent pharmacies.
GoodRx Holdings: Failing To Gain Much Traction
Today, we are circling back on GoodRx Holdings, which offers a platform for comparing prescription drug prices. The company also enables their customers to benefit from negotiated prices through GoodRx codes that are used to save money on prescriptions. The stock has a bit of a rocky ride since forward guidance disappointed following second-quarter results.
ELV vs. GDRX: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors with the better value opportunity right now?
GoodRX Subscription Revenue Down 8% but Active User Numbers Are Up
It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million.
GoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom - Raymond James Stephanie Davis - Barclays Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Kevin Caliendo - UBS Allen Lutz - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Rx Second Quarter 2024 Earnings Call. As a reminder, today's conference call is being recorded.
